VYNE Therapeutics Inc.
VYNE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | -$0 | $0 |
| Enterprise Value | $0 | -$0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 18.2% | -11.1% | -48.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -8,709.2% | -6,900.5% | -7,174.6% | -4,167.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -7,950.9% | -6,710.4% | -4,865.8% | -7,876.4% |
| EPS Diluted | -0.94 | -2.77 | -10.65 | -25.65 |
| % Growth | 66.1% | 74% | 58.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |